Kenvue stock holds near $19 after dividend and buyout watch
Published on 08/27/2026 at 17:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Shares stay close to the offer zone
Kenvue Inc. (US49177J1025) is trading at $19.33 as of August 27, 2026, with an intraday market value of $37.129 billion and a 52-week range of $14.02 to $20.95. The stock is also still inside the narrow band around its consensus target of $19.27, which leaves little room between the current quote and the average view.
MarketBeat shows the shares at $19.23 as of August 26, 2026 at 3:58 p.m. Eastern, while Yahoo Finance showed $19.33 at 11:48 a.m. EDT on August 27, 2026. That same quote page puts the year-to-date move at 12.06 percent and the five-day move at 1.05 percent.
Dividend and earnings keep mattering
The latest reported quarter is Q2 2026, when Kenvue posted revenue of $3.96 billion and earnings of $0.31 a share, while the market expected $0.32. Revenue still rose 3.0 percent year over year, giving the quarter a modest top-line gain even as the EPS line came in one cent short of consensus.
That mix matters because the company is now yielding 4.35 percent, with a $0.21 quarterly dividend that was paid on August 26, 2026 after the August 12, 2026 ex-dividend date. Kenvue also reported trailing revenue of $15.41 billion, net income of $1.66 billion, and levered free cash flow of $1.91 billion, so the market is still weighing cash generation against a stock that already reflects much of the known story.
What the chart says
The one-year trading range is wide enough to keep the setup active, from $14.02 on the low end to $20.95 on the high end. At $19.33, the shares sit 7.8 percent below that 52-week peak and 37.8 percent above the low, which keeps the tape constructive without pushing it into breakout territory.
Volume on the latest session reached 13,189,014 shares, below the 20,839,509 average volume shown on Yahoo Finance, while MarketBeat listed 25.40 million shares and a market cap of $36.94 billion at its August 26, 2026 close snapshot. That gap between volume and average trading activity suggests the stock is still being watched, but not chased.
Zyrtec adds a product angle
Kenvue has been promoting Zyrtec Allergen Shield Spray, a consumer-health extension that fits the company's self-care and allergy portfolio. For a group built around brands such as Tylenol, Listerine, Neutrogena, and Zyrtec, product launches like that help explain why the company can still pair slow growth with a premium cash-return profile.
Price and setup
Kenvue shares were last quoted at $19.33 as of August 27, 2026 at 11:48 a.m. EDT, and the stock remains close to its average target of $19.27. With a market cap of $37.129 billion and Q2 2026 EPS of $0.31, the next move is likely to depend on whether investors keep paying up for yield and cash flow or demand clearer growth.
More on Kenvue stock
Kenvue Inc. focuses on consumer health across self care, skin health and beauty, and essential health, with brands sold through retail, pharmacy, and e-commerce channels.
Investor details
Company: Kenvue Inc.
ISIN: US49177J1025
Ticker: KVUE
Exchange: NYSE
Sector / Industry: Consumer Staples / Personal Care Products
Index membership: S&P 500
